MA-ALIRA-HEALTH
25.1.2022 15:02:11 CET | Business Wire | Press release
Alira Health (www.alirahealth.com ), a global healthcare consulting and technology firm, announced that it has acquired Self Care Catalysts, Inc., a digital health company headquartered in Toronto, Canada. Self Care Catalysts focuses on patients and puts them at the center of human networks, technology, and science. Self Care Catalysts’ digital health platform, Health Storylines™, helps patients gain an intimate understanding of their health journey while managing their conditions and generating clinical and real-world evidence along the way. Health Storylines enables over 120,000 patients to be active and informed owners of their healthcare data across more than thirty major therapeutic areas. This is Alira Health’s third patient-centric digital health acquisition in the last four months and the first in North America.
“Today, it’s more important than ever to give patients and their care-giving circles the ability to map their own healthcare journeys. Self Care Catalysts derives their success from putting patients first and then extending their platform to help pharmaceutical, biotech and medtech clients streamline their efforts to bring new medicines and devices to market through direct patient access for Decentralized Clinical Trials (DCT) and Real World Evidence (RWE),” said Gabriele Brambilla, co-founder and CEO of Alira Health. “The acquisition of Self Care Catalysts is a strategic addition to our growing global portfolio of patient-centric technologies, making Alira Health a leading player in North America and Europe in DCT and patient-centric RWE solutions with over 150 studies run in partnership with over 250,000 patients.”
“Health Storylines helps patients make sense of their healthcare journey through meaningful data that they own and control. Patients choose to donate or share their data for a good cause, whether it is for clinical research, to inform policy makers, to seek help from their care providers with holistic data for better treatment planning, or simply to gain peace of mind,” said Grace Almendras-Castillo, Founder and CEO of Self Care Catalysts. “We share Alira Health’s mission to humanize healthcare and are pleased to become part of a company poised to transform healthcare.”
Self Care Catalysts’ co-founders Grace Almendras-Castillo and Jared Adams will assume leadership roles at Alira Health in the development of digital patient and consumer health solutions in North America.
About Self Care Catalysts
Self Care Catalysts is a patient-driven clinical and real-world evidence, analytics and digital therapeutics company designed to inform care management, treatment decisions, product life cycle management and behavior change interventions. More information may be obtained at https://www.selfcarecatalysts.com and https://www.healthstorylinescreator.com .
About Alira Health:
Alira Health is an international patient-centric and technology-enabled advisory firm whose mission is to humanize healthcare. We work with healthcare and life sciences organizations looking for support across their entire solutions lifecycle. From development to medical care, we complement our clients’ expertise with a full spectrum of services including research and clinical development solutions, technology-powered consulting, and real-world evidence.
Our integrated and multidisciplinary team of over 500 scientists, strategists, economists, clinicians, and biostatisticians collaborate across our North American, European, and Asian offices and advise 80% of the top 50% of MedTech companies and 50% of the top 50% of Pharma companies.
Learn more at https://www.alirahealth.com/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220125005020/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NIQ Publishes 2026 ESG Progress Report, Highlighting Action Across Climate, People, Communities, and Responsible AI2.11.2026 12:45:00 CET | Press release
Report details NIQ’s continued focus on responsible business, including its first climate risk assessment, expanded employee development and more than 100,000 volunteer hours NIQ (NYSE: NIQ), a leading consumer intelligence company, today released its 2026 Environmental, Social and Governance (ESG) Progress Report, detailing the company’s progress on key ESG priorities throughout 2025. The report covers NIQ’s efforts across environmental responsibility, its people and communities, data integrity, and responsible AI. Key highlights from 2025 include:Strengthened its approach to climate risk and environmental measurement: NIQ conducted its first climate risk assessment aligned with Task Force on Climate-related Financial Disclosures (TCFD) recommendations, tracked Scope 1, 2 and 3 emissions under the GHG Protocol, and externally verified its carbon footprint. Invested in associate development, engagement and well-being: Internal mobility increased to 35%, up from 30%, while performance r
Agenus Announces Nature Medicine Publication of Multicenter UNICORN Phase 2 Trial Demonstrating Deep Responses with Neoadjuvant BOT+BAL in Resectable Colon Cancer2.11.2026 12:42:00 CET | Press release
In pMMR/MSS colon cancer, neoadjuvant BOT+BAL met the trial’s primary endpoint with a 36% major pathologic response rate, including 29% pathologic complete response, within an overall 71% pathologic response rate after one BOT dose and two BAL dosesNo patients treated with BOT+BAL had their cancer return, with median follow-up of 19.2 months in MSS disease and 16.7 months in MSI-H disease; 12-month event-free survival was 100% in both combination cohorts.Independent, multicenter UNICORN findings reinforce the NEST peer-reviewed neoadjuvant evidence supporting Agenus’ planned Phase 3 ROBBIN trial in curative-intent MSS/pMMR colon cancer Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of results from the investigator-sponsored, multicenter Phase 2 UNICORN trial evaluating short-course preoperative, or neoadjuvant, botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, alone or in combination with ba
New Joint Survey from Compass Pathways and the Depression and Bipolar Support Alliance Reveals the Lived Burden of Treatment-Resistant Depression on Patients and Caregivers2.11.2026 12:30:00 CET | Press release
New survey findings reveal the extent of unmet need for people living with treatment-resistant depression (TRD) and its impact on families, relationships and the ability to participate fully in everyday life Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, in partnership with the Depression and Bipolar Support Alliance (DBSA), today released a new report summarizing findings from a national survey of people living with TRD (n=261) and caregivers (n=73) on the self-reported realities of living with a condition that can profoundly affect daily life, revealing the burden of prolonged depressive episodes without meaningful relief. The survey findings demonstrate the impact of TRD across various aspects of everyday life, with many patients reporting years spent cycling through treatments without significant improvement while the condition takes a toll on their hope, identity, relationships and ab
Qorium Becomes Reyva as Cultivated Leather Company Moves Towards Commercial Scale2.11.2026 11:00:00 CET | Press release
New identity signals the company’s evolution into a standalone material brand for luxury and automotive markets Reyva develops real leather by cultivating bovine collagen from a small sample of animal cells. The new brand brings together advanced biotechnology, leather expertise and a clearer luxury proposition. The company’s team, technology, partnerships and commercial ambition continue under the new name. Qorium, the company that develops cultivated real leather, today announces that it is becoming Reyva. The new name and identity mark its next stage: moving from a pioneering technology business towards a global material brand built for the exacting standards of the luxury leather sector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261102661351/en/ Reyva creates beautiful, high-performing real leather. By cultivating leather in uniform sheets, we can move beyond the natural limits of traditional hides, with greater con
Ant International Research Highlights How Readable AI Memories Can Unlock More Personalised, Privacy-conscious Consumer Experiences2.11.2026 09:52:00 CET | Press release
Human sales and customer representatives have institutional memories to serve clients: their preferences and choices. How can we build a memory mechanism for AI services to create similarly personalised experiences? Ant International’s research on this subject recently received the Senior Area Chair (SAC) Highlight Award from the Best Paper Committee at EMNLP 2026, a leading global AI conference. Why do we need “readable AI memory”? In this paper titled 'Text as a universal interface for transferable personalisation', we look into one fact: until now, AI memory of a user has usually been generated and stored as dense numerical code only the original system can interpret. Two long-standing problems with that: First, today's user profiles are "black boxes" — opaque code locked inside a single app, so activity in one service teaches nothing to another, and every product has to re-learn you from scratch. Second, profiles are welded to the model that created them, so they don't transfer whe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom